Back

Quality of life and clusters of patient characteristics in individuals with statin intolerance

1 September 2024 (14:00 - 14:50)
Organised by: Logo
Congress Presentation Part of: Lipid-lowering drugs: new insights Lipids ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Paulina Elena Stuerzebecher

University hospital Leipzig AoR, Leipzig (Germany)

7 More presentations in this session

Presentation thumbnail
The cardiovascular polypill strategy (acetyl salicylic acid, atorvastatin, ramipril) as baseline treatment after a cardiovascular event supported by compelling evidence: a global expert consensus
Doctor J. Gonzalez Juanatey (Santiago de Compostela, ES)
Abstract Slides Video
Presentation thumbnail
Combination of moderate-intensity statins and ezetimibe versus high-intensity statins alone for primary prevention of cardiovascular events
Doctor L. Godoy (Ottawa, CA)
Abstract Slides Video
Presentation thumbnail
Proprotein convertase subtilisin/kexin type 9 levels and the risk of cardiovascular events in statin-treated patients with cardiovascular disease
Assistant Professor M. Gohbara (Yokohama, JP)
Abstract Slides Video
Presentation thumbnail
Safety and Efficacy of Moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease: a meta-analysis
Doctor F. Alves Kelly (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Efficacy and severity of side-effects of rosuvastatin compared to other statins post-heart-transplantation
Ms B. Van Dijk (Rotterdam, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid-lowering drugs: new insights

The Event

Event poster

ESC Congress 2024

1 September 2024 14:00 CET
You may be interested in
thumbnail
Congress Presentation
The SLCO1B1 c.521 T > C variant is not associated with muscular symptoms or PCSK9-inhibitor prescription in patients with severe hypercholesterolemia
thumbnail
Congress Presentation
Optimising oral lipid-lowering therapy regimens in high and very high-risk statin intolerant patients with dyslipidaemia: A French real-world simulation
thumbnail
Congress Presentation
Plasma statin concentrations do not correlate with statin-induced myalgia

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources